Bill 118 hr 10239, also known as the Drug Shortage Notification Act, aims to amend the Federal Food, Drug, and Cosmetic Act to address drug shortages caused by sudden increases in demand. The bill requires drug manufacturers to notify the Food and Drug Administration (FDA) of any anticipated shortages or surges in demand for their products.
The purpose of this legislation is to improve transparency and communication between drug manufacturers, the FDA, and healthcare providers in order to better manage and prevent drug shortages. By expanding notification practices to include surges in demand, the bill seeks to ensure that healthcare providers are aware of potential shortages and can take appropriate measures to address them.
Overall, the Drug Shortage Notification Act is designed to help mitigate the impact of drug shortages on patient care and public health by promoting early detection and response to supply disruptions. This legislation is an important step towards ensuring the availability of essential medications for all Americans.